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Objective: A review of the peri-operative risk associated with hepatic resection in patients with meta-
bolic syndrome (MetS) and identification of measures for the improvement of cardiometabolic
disturbances and liver-related mortality.
Background: MetS and its hepatic manifestation non-alcoholic fatty liver disease (NAFLD) are associ-
ated with an increased operative mortality in spite of a significant improvement in peri-operative outcome
after hepatic resection.
Methods: A review of the English literature on MetS, liver resection and steatosis was performed from
1980 to 2011 using the MEDLINE and PubMed databases.
Results: MetS is a predictor of NAFLD and patients with multiple metabolic risk factors may harbour
non-alcoholic steatohepatitis (NASH) predictive of operative and cardiovascular mortality. Pre-operative
diagnosis of unsuspected NASH with the selective use of a liver biopsy can modify the operative strategy
by limiting the extent of hepatic resection, avoiding or altering the pre-operative chemotherapy regimen
and the utilization of portal vein embolization. Thiazolidinediones are therapeutic for MetS and NASH and
Vitamin E for active NASH; however, their utility in improving the peri-operative outcome after hepatic
resection is unknown. A short-term regimen for weight loss improves post-operative patient and liver-
related outcomes in patients with >30% steatosis. Cardiovascular disease associated with MetS or
NAFLD should be managed aggressively. Peri-operative measures to minimize thrombotic events and
acute renal injury secondary to the pro-inflammatory, prothrombotic state of MetS may further improve
the outcome.
Conclusion: Potential candidates for hepatic resection should be screened for MetS as the pre-
operative identification of NASH, short-term treatment of significant steatosis, cardiovascular risk assess-
ment and optimization of each component of MetS may improve the peri-operative outcome in this
high-risk subset of patients.
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Introduction
Metabolic syndrome (MetS) is a constellation of inter-related risk
factors of metabolic origin including abdominal obesity, athero-
genic dyslipidemia, hypertension, insulin resistance and a pro-
inflammatory prothrombotic state which has an adverse impact
on the peri-operative outcome.1–9 Patients with MetS have a two-
fold risk of operative mortality and are at an increased risk for
cardiac events, acute kidney injury, stroke and infectious compli-
cations. MetS is prevalent in 23.7% of adults and 43.5% of adults
aged >60 years in the United States and non-alcoholic fatty liver
disease (NAFLD) is widely accepted as the hepatic manifestation
of MetS.10,11 MetS is prevalent in 36% NAFLD, 67% obese NAFLD
and 88% patients with NASH.12,13 It is important to identify the
presence of MetS in NAFLD patients as they frequently have
advanced histologic injury of the liver and an elevated risk of
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mortality from cardiovascular disease (CVD) and liver-related
causes.13–15 Over the past two decades, high-volume centres have
reported a significant decline in operative mortality after hepatic
resection; however, the presence of30% hepatic steatosis is asso-
ciated with a three-fold risk of mortality and a two-fold risk of
post-operative morbidity.16–23
Optimization of peri-operative outcome in this high-risk
subset of patients requires treatment of the individual compo-
nents of MetS, NAFLD and CVD. Insulin sensitizers including
thiazolidinediones (TZD) are beneficial in the treatment of MetS
and NASH as insulin resistance is central to their development.24,25
Vitamin E has demonstrated therapeutic efficacy in the reduction
of the histologic severity of steatosis and NASH.26 A short-term
regimen for pre-operative weight loss improves patient and liver-
related outcome in patients with >30% steatosis.27 Patients with
multiple metabolic risk factors may harbour unsuspected NASH
identifiable by a liver biopsy which will determine the extent of
hepatectomy and the use of pre-operative chemotherapy or portal
vein embolization (PVE). Peri-operative measures to minimize
cardiovascular risk, thrombotic events and acute renal injury asso-
ciated with MetS may further improve the outcome.5–9 The
present study is a review of the peri-operative risk associated with
hepatic resection in patients with MetS with the objective of iden-
tifying measures for the improvement of cardiometabolic risk and
liver-related mortality.
Methods
A search of the English literature for articles published between
1980 and 2011 was performed using the MEDLINE database with
PubMed and Ovid as search engines. The keywords included
metabolic syndrome, liver resection and steatosis. All titles and
abstracts of the publications were screened and relevant articles
were retrieved excluding case reports. The reference lists of the
retrieved articles were reviewed for potentially related studies and
relevant articles were selected.
Metabolic syndrome
MetS has existed in various forms and definitions for over eight
decades; however, it is only recently that its significance and the
need for a unified definition have emerged. The National Cho-
lesterol Education Program’s Adult Treatment Panel III report
(NCEP-ATP III) identified MetS as a multiplex risk factor which
doubles the risk for atherosclerotic CVD.15,28 In a meta-analysis
of MetS and the risk of CVD, MetS significantly increased all-
cause and CVD-related mortality as well as the incidence of
CVD and stroke.29 In 1988, Reaven noted that several risk factors
cluster together and called it Syndrome X or insulin resistance
syndrome as insulin resistance is a key component conferring
increased risk for type 2 diabetes and CVD.30 ATP III prefers the
term metabolic syndrome and has identified six components:
abdominal obesity, atherogenic dyslipidemia, hypertension,
insulin resistance, pro-inflammatory and prothrombotic state of
which the last five components are termed metabolic risk
factors.1
Diagnostic criteria for MetS
Several diagnostic criteria have been proposed by different orga-
nizations and most recently they have come from the Interna-
tional Diabetes Federation (IDF) and the American Heart
Association/National Heart, Lung and Blood Institute (AHA/
NHLBI). The main difference concerns waist measurement, the
measure for central obesity, which is an obligatory component of
the IDF criteria. In a consensus meeting of several major organi-
zations attempting to unify the diagnostic criteria it was agreed
upon that there should not be an obligatory component, however,
waist measurement would continue to be a useful preliminary
screening tool.31 Three out of five abnormal findings would
qualify a person for the diagnosis of MetS as shown in Table 1.
Measurement of waist circumference is ethnic-specific and the use
of national or regional cutpoints was recommended. The recom-
mended waist circumference threshold for abdominal obesity in
United States is 102 cm and 88 cm in men and women,
respectively.32
Pathogenesis of MetS
The AHA/NHLBI identified three potential aetiologic categories:
obesity and disorders of adipose tissue, insulin resistance and a
constellation of independent factors of hepatic, vascular and
immunologic origin.33
Abdominal obesity
The NCEP-ATP III recommendation to measure waist circumfer-
ence in the diagnosis of MetS rather than body mass index (BMI)
Table 1 Criteria for the clinical diagnosis of metabolic syndrome
[Alberti KG et al. Circulation 2009; 120 (16):1640–1645)31
Measure Categorical Cut Points
Increased waist circumference Population-specific and
country-specific definitions
Increased triglycerides (drug
treatment for elevated TG is
alternate indicator)
150 mg/dl
Reduced HDL cholesterol (drug
treatment for reduced HDL is
alternate indicator)
<40 mg/dl in males
<50 mg/dl in females
Increased blood pressure
(antihypertensive drug
treatment in patient with
history of hypertension is
alternate indicator)
Systolic 130 and/or
Diastolic 85 mm Hg
Increased fasting glucose (drug
treatment of increased
glucose is alternate indicator)
>100 mg/dl
The diagnosis of metabolic syndrome requires three out of five abnormal
findings. HDL, high-density lipoprotein; TG, triglycerides.
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recognizes its greater accuracy in the assessment of cardiometa-
bolic risk and the close correlation with visceral adiposity.34
Impaired metabolism of non-esterified fatty acids (NEFA) con-
tributes to the insulin-resistant state in visceral obesity and the
excess energy instead of being channelled into the insulin-
sensitive subcutaneous adipose tissue and protecting against the
development of MetS is deposited at undesirable sites such as the
liver, heart, skeletal muscle and visceral adipose tissue – a phe-
nomenon described as ectopic fat deposition as shown in Fig. 1.34
The dysfunctional visceral adipose tissue is characterized by a
hyperlipolytic state resistant to the anti-lipolytic effect of insulin
leading to NEFA flux to the liver promoting a fatty liver and
atherogenic dyslipidemia.
Insulin resistance
Several investigators consider insulin resistance and its accomplice
hyperinsulinemia as the key mechanism in the development and
manifestations of MetS.33 Homeostasis Model Assessment
(HOMA) is used for the quantitative assessment of insulin resis-
tance and deficient b-cell function utilizing the patient’s fasting
plasma insulin and glucose concentrations.35 Insulin resistance
rises with increasing body fat content andmost people with a BMI
30 kg/m2 have postprandial hyperinsulinemia with relatively
low insulin sensitivity.36 Insulin resistance in muscle predisposes
to glucose intolerance which is worsened by increased hepatic
gluconeogenesis in an insulin-resistant liver.1
Pro-inflammatory state
Adipose tissue specializing in the storage of lipids is also an impor-
tant endocrine organ releasing numerous hormones, adipocytok-
ines and pro-inflammatory molecules such as interleukin-6 (IL-6)
and tumor necrosis factor-a (TNF-a) contributing to the inflam-
matory profile of the abdominally obese patients.37,38 A pro-
inflammatory state recognized clinically by the elevation of
C-reactive protein (CRP) is commonly present in MetS and CRP
3 mg/l is a risk factor for CVD.28,39,40 Low levels of adiponectin in
blood is a salient feature of visceral obesity responsible for the
Figure 1 The channelling of surplus calories from excess dietary
consumption and sedentary lifestyle into insulin-sensitive subcuta-
neous adipose tissue will protect against the development of meta-
bolic syndrome. However, in the presence of dysfunctional adipose
tissue, genetic predisposition and a neuroendocrine profile related to
a maladaptive response to stress, the triacylglycerol surplus will be
deposited at undesirable sites such as the liver, heart, skeletal
muscle and visceral adipose tissue – a phenomenon known as
ectopic fat deposition. Metabolic consequences of this defect in
energy partitioning include visceral obesity, insulin resistance,
atherogenic dyslipidemia and a prothrombotic proinflammatory
profile the defining features of metabolic syndrome. Reprinted by
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atherogenic, diabetogenic and proinflammatory profile of MetS
and is associated with an increased risk of a myocardial
infarction.41–43
Prothrombotic state
A prothrombotic state characterized by increased plasma plasmi-
nogen activator inhibitor (PAI)-1 and fibrinogen is associated
with MetS.44,45 Fibrinogen and acute-phase reactants such as CRP
rise in response to a high-cytokine state suggesting that the pro-
thrombotic and proinflammatory states may be metabolically
interconnected.46–48
Non-alcoholic fatty liver disease
NAFLD is a spectrum of fatty liver infiltration from simple ste-
atosis (NAFL) to necroinflammation and fibrosis (NASH). The
prevalence of NAFLD in asymptomatic US adults estimated on
the basis of unexplained elevation of amoinotransferases on the
third National Health and Nutrition Examination Survey
(NHANES-III) was 7.9% and strongly correlated with the pres-
ence of MetS.49,50 Unlike simple steatosis, NASH is a progressive
liver disorder and it is estimated that 10–25% of those with
NAFLD will develop NASH and 5% will progress to cirrhosis
and liver failure.51–54 NAFLD is an important cause of liver-
related morbidity and mortality and increases CVD-related mor-
tality independent of MetS.55–57 Analysis of the NHANES-III
participants including 980 with NAFLD and 6594 without
NAFLD demonstrated that the former had a significantly higher
all-cause [hazard ratio (HR) 4.10, 95% confidence interval (CI)
1.27–13.23] and cardiovascular mortality (HR 8.15, 95% CI
2.00–33.2) in the 45–54 years age group after adjusting for con-
ventional cardiovascular risk factors.55 The authors concluded
that NAFLD is a strong independent risk factor for cardiovascu-
lar death and warrants modification of CVD risk management
guidelines.
The precise pathogenesis of NASH is unclear; however, the two
‘hit’ theory is most widely accepted wherein the first hit is hepatic
steatosis secondary to obesity or MetS and the second hit includes
insulin resistance, oxidative stress and abnormal cytokine produc-
tion which plays a key role in hepatocellular injury, inflammation
and fibrosis.58–60 Insulin resistance is nearly universal in NASH and
plays an important role in its pathogenesis by promoting periph-
eral lipolysis and de novo lipogenesis.61,62 Circulating levels of IL-6
a proinflammatory cytokine elevated in MetS demonstrated a
positive correlation with hepatic IL-6 expression, degree of
inflammation, fibrosis and systemic insulin resistance in patients
with NASH.63
Radiologic assessment of NAFLD
The adverse impact of steatosis and chemotherapy-associated
liver injury on peri-operative outcome after liver resection is well
recognized emphasizing the importance of its pre-operative
recognition.17–23 Liver biopsy the reference for diagnosis and
quantification of steatosis provides an accurate diagnosis
in 90% patients; however, it is limited by its invasive nature,
mortality rate of 1 in 10 000 and sampling variability.64–70
Radiologic investigations, the non-invasive alternative to
liver biopsy, have demonstrated wide variability in their sensitiv-
ity and specificity for the detection and quantification of
steatosis.71
More recently, in vivo proton magnetic resonance spectros-
copy (MRS) [hydrogen 1 (1H) MR spectroscopy] has emerged as
the reference standard in several clinical studies.72–74 However, 1H
MR spectroscopy is time-consuming and has limited availability.
Several modifications of the MR technique have been used with
results similar to MRS.75–80 In a comparative study of the diag-
nostic performance of ultrasonography (US), computed tomog-
raphy (CT), T1-weighted MR imaging and 1H MR spectroscopy
in the preoperative assessment of steatosis in patients undergo-
ing liver resection, MR imaging and MR spectroscopic measure-
ments of hepatic fat had a significantly stronger correlation with
histologic assessment and were able to differentiate between the
3 grades of steatosis: none, mild, moderate and severe unlike US
and CT.81 The sensitivities of US, CT, T1-weighted MR imaging
and MR spectroscopy were 65%, 74%, 90% and 91% and speci-
ficities were 77%, 70%, 91% and 87%, respectively. This led the
authors to conclude that T1-weighted MR imaging and 1H MR
spectroscopy had the best diagnostic accuracy and strongly cor-
relate with the histologic assessment and grade of steatosis. MR
elastography measuring liver stiffness demonstrated high accu-
racy in distinguishing simple steatosis from NASH even before
the onset of fibrosis with a sensitivity of 94% and specificity of
73% using a threshold of 2.74 kPa.82 NAFLD patients with
inflammation and no fibrosis had greater liver stiffness than
those with simple steatosis and lower mean stiffness than those
with fibrosis.
Pre-operative planning for a hepatectomy is usually based on
CT findings and MR imaging is not performed routinely. In a
prospective determination of the diagnostic performance of
unenhanced CT in the assessment of 30% macrovesicular ste-
atosis in potential donors for living donor liver transplantation
using same-day biopsy as a reference standard, Park et al. reported
that a liver-to-spleen (L/S ratio) attenuation ratio of 0.8 and a
difference between liver and splenic attenuation of -9 yielded a
100% specificity and 82% sensitivity for both indices.83–85 The
authors concluded that unenhanced CT is not clinically acceptable
for quantitative assessment, however, provides high performance
in the qualitative diagnosis of macrovesicular steatosis30%. In a
randomized placebo-controlled study of healthy individuals diag-
nosed with radiographically defined NAFLD based on a L/S ratio
<1 on CT scan indicative of >30% hepatic steatosis, antioxidant
and statin therapy significantly reduced the odds of having
NAFLD at the end of follow-up.54 While these results will require
validation in a trial with a liver biopsy as an end point, they
demonstrate the utility of a CT scan in the radiographic diagnosis
of NAFLD.
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Pathologic assessment of NAFLD
The Pathology Committee of the NASH Clinical Research
Network designed and validated a histologic scoring system based
on the grading proposal of Brunt et al. that addresses the full
spectrum of lesions of NAFLD and proposed a NAFLD activity
score (NAS) for use in clinical trials.86,87 NAS specifically includes
only features of active injury that are potentially reversible in the
short term. The score is defined as the unweighted sum of the
scores for steatosis (0–3), lobular inflammation (0–3) and bal-
looning (0–2) thus ranging from 0–8 as shown in Table 2. Fibrosis
is not included in the scoring system as it is less reversible and
considered a consequence of disease activity which is an accepted
paradigm for staging and grading of NASH.87 NAS5 correlated
with a diagnosis of NASH and biopsies with scores <3 were diag-
nosed as ‘not NASH.’ The inter-observer agreement was 0.84 for
fibrosis, 0.79 for steatosis, 0.56 for injury and 0.45 for lobular
inflammation. The authors concluded that NAS was a strong
scoring system with reasonable inter-observer variability that
should be useful for clinical studies in both adults and children
with any degree of NAFLD.
Impact of MetS on surgical outcome
MetS adversely impacts peri-operative outcome in patients under-
going cardiac and non-cardiac operations.2–7 In a retrospective
review of 5304 consecutive patients who underwent coronary
artery bypass graft (CABG) surgery, 46% patients met the diag-
nostic criteria for MetS and it was a strong independent predictor
of operative mortality (2.4% vs. 0.9%).4 Patients with MetS had a
significantly higher incidence of post-operative stroke, renal
failure and infectious complications attributable to an exacerba-
tion of the low-grade inflammatory and prothrombotic state of
MetS by the systemic inflammatory response to cardiopulmonary
bypass and operative stress.88 Moreover, patients with MetS have
systemic oxidative stress secondary to the increased oxidative
transformation of low-density lipoprotein.89 The authors recom-
mendmodification of the components of MetS with pre-operative
dietary changes, an increase in physical activity and peri-operative
glucose homeostasis for an improvement in outcome. CRP and
albumin levels are considered as parameters of systemic inflam-
mation and a combination of CRP 10 mg/l and albumin level
35 g/l in the Glasgow Prognostic Score for cancer is an indepen-
dent predictor of peri-operative morbidity and mortality in
patients with oesophageal and colorectal cancer.90,91 Other authors
have identifiedMetS as a risk factor for post-operative atrial fibril-
lation, acute kidney injury, myocardial infarction and stroke.5–7
In a review of 310 208 patients with modified MetS based on
obesity as the American College of Surgeons National Surgical
Quality Improvement Program (ACS-NSQIP) database does not
include information on abdominal circumference, presence of
MetS was associated with a two-fold risk of death, 2.5-fold risk of
cardiac adverse events and a three- to seven-fold higher risk
of acute kidney injury leading the authors to conclude that ‘meta-
bolically obese’ patients have a dramatically higher risk of com-
plications after non-cardiac surgery.2 Other authors have also
reported a higher rate of complications and longer hospital stay in
patients with MetS undergoing elective surgery for colorectal
cancer.3
Several authors have reported a significantly higher prevalence
of MetS in patients with idiopathic venous thromboembolism
(VTE).9,92–94 In a case–control study to investigate the presence of
MetS in patients with confirmed VTE, 116 patients were com-
pared with 129 healthy controls and the prevalence of MetS was
significantly higher in patients with VTE, 35% vs. 20%.92 Indi-
viduals with MetS had significantly higher levels of high-
sensitivity CRP, fibrinogen and factor VIII activity compared with
those without MetS. The authors concluded that MetS is associ-
ated with a two-fold increased risk of VTE and may contribute to
its development.
Impact of MetS on outcome after hepatic resection
There are several studies which evaluate the impact of steatosis on
peri-operative outcome after hepatic resection, however, none
specifically evaluate the outcome in patients with MetS.17–22 Fur-
thermore, most of these studies have classified the degree of ste-
atosis into mild, moderate and severe based on the presence of fat
vacuoles in the cytoplasm of <30%, 30–60% and >60% hepato-
cytes without application of the NAS system for distinguishing the
presence of steatohepatitis associated with a higher risk of liver
failure and death after a major hepatectomy.23,86,95 An important
element of the NAS system is that NAFLD can manifest with
steatohepatitis in the presence of minimal steatosis.96
Table 2 NAFLD activity score (NAS) [Kleiner DE et al. Hepatology
2005; 41 (6): 1313–1321]86
Pathologic feature Definition Score
(0–8)





Lobular inflammation Assessment of inflammatory foci
No foci 0
<2 foci per 200¥ field 1
2–4 foci per 200¥ field 2
>4 foci per 200¥ field 3
Ballooning Liver cell injury
None 0
Few balloon cells 1
Many cells/ prominent ballooning 2
NAS 5, definite NASH; NAS 3–4, borderline NASH; NAS <3, not
NASH; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic
steatohepatitis.
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Transplantation of liver with severe steatosis is associated with
a high risk of primary non-function in contrast to mildly steatotic
grafts which yield results similar to non-steatotic livers.97,98 Fatty
hepatocytes have a reduced tolerance to ischemia/reperfusion
injury demonstrating a predominantly necrotic form of cell death
owing to microcirculatory failure as opposed to apoptosis a key
feature of ischaemic injury in the normal liver.99 Hepatocellular
necrosis leads to the release of cytoplasmic contents which further
increase the inflammatory response and liver injury. In addition,
the ability of hepatocytes to regenerate after major tissue loss is
impaired in the steatotic liver further contributing to the morbid-
ity and mortality of hepatic resection.100
A meta-analysis of 1000 patients demonstrated a significantly
increased risk of post-operative morbidity and mortality with
moderate or greater steatosis after major hepatic resection.18
Several authors have confirmed steatosis as an independent pre-
dictor of complications after hepatic resection with a positive
correlation between the degree of steatosis and post-operative
hepatic insufficiency and an insignificant trend towards increased
mortality with lobe or greater resections as shown in Table 3. Data
on the influence of alcohol-related liver injury on peri-operative
outcome after hepatic resection are limited with Kooby et al.
reporting a similar incidence of heavy alcohol use in the steatotic
and control groups.21 Little et al. reported a significantly greater
operative mortality in diabetic patients undergoing hepatic resec-
tion compared with non-diabetic patients (8% vs. 2%) and the
long-term survival was identical highlighting the increased peri-
operative risk in these patients.101 Four of the five deaths were as a
result of liver failure of which three patients had steatosis. McCor-
mack et al. in a matched case–control study reported a mortality
of 8.5% with steatotic livers compared with 1.7% in patients with
lean livers [P = non-significant (NS)]. Mortality was not liver
related and attributed to mesenteric infarction (n = 1), sepsis and
multi-organ failure (n = 3) and cardiac failure (n = 1).19 They also
reported a significantly higher incidence of major complications
in the steatotic group (27% vs. 5%) and all four patients with renal
failure and VTE were in the steatotic group. These data suggest
that patients undergoing liver resection in the presence of steatosis
are at an increased peri-operative risk not only from liver-related
causes but also the systemic manifestations of MetS.
Impact of pre-operative chemotherapy on NAFLD
Chemotherapy-associated steatohepatitis (CASH) based on NAS
4 criteria is associated with a significant increase in 90-day mor-
tality after hepatic resection (14.7% vs. 1.6%).23 Use of irinotecan
was associated with an increased risk of steatohepatitis and the
effect was more pronounced in patients with a higher BMI (12.1%
in BMI <25 kg/m2 and 24.6% in BMI 25 kg/m2) suggesting
that obesity and pre-existing steatosis are risk factors for the
development of CASH.23,102,103 The authors also reported a
direct correlation between increasing BMI and the severity of
chemotherapy-associated liver injury.102 In contrast, the use of
5-fluorouracil (5-FU) was associated with the development
of steatosis without steatohepatitis in 47% of patients.104
The key molecular event underlying the development of CASH
is the production of reactive oxygen species (ROS) resulting in
oxidative stress in the hepatocytes.105,106 A two-hit theory for the
development of CASH proposes that obesity rendering the liver
susceptible to oxidative stress is the first hit and chemotherapy
results in the second toxic hit.107 The generally higher BMI in the
Table 3 Impact of hepatic steatosis on peri-operative outcome after hepatic resection
Author Year N Steatosis N Mortality (%) Morbidity (%)
Behrns22 1998 135 None 72 3 4
Mild 56 7 9
Moderate-severe 7 14 14
Belghiti17 2000 478 Absent 441 1 8
Present 37 0 22
Little101 2002 727 Absent 505 2.0 37
Present 222 4.9 45
Kooby21 2003 485 None 160 5 35
Mild 223 5 48
Moderate-severe 102 9.4 62
Gomez20 2007 386 None 192 1 22
Mild 122 2.5 43
Moderate 60 3 62
Severe 12 0 58
McCormack19 2007 116 Absent 58 1.7 25
Present 58 8.6 50
Mild steatosis, <30% hepatocytes involved; moderate steatosis, 30–60% hepatocytes involved; severe steatosis, >60% hepatocytes involved.
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North American population compared with the European popu-
lation may explain why the US study reported steatohepatitis and
European studies reported vascular changes as the dominant
pattern of chemotherapy-associated liver injury.102,103,108–110 These
data suggest that irinotecan and oxaliplatin probably affect pro-
gression but not the development of steatosis.
Therapeutic strategies to improve outcome
after hepatic resection in MetS
MetS increases the risk for advanced NAFLD and CVD suggesting
that potential candidates for hepatic resection should be screened
for the presence of MetS and the optimization of surgical outcome
in this particularly high-risk subset of patients will require a mul-
tidisciplinary effort to treat individual components of MetS and
NAFLD in consultation with a cardiologist and hepatologist.111–113
Management of MetS
The primary goal in the management of MetS is the reduction in
the risk of clinical atherosclerotic disease.114 First line therapy is
directed towards the major risk factors of elevated LDL choles-
terol, hypertension and diabetes with the emphasis on lifestyle
interventions including weight reduction, dietary modification,
increased physical activity and drug therapy should be considered
based on the individual cardiovascular risk.115 TZDs a peroxisome
proliferator-activated receptor-g (PPARg) agonist class of drugs
ameliorate insulin resistance and the pro-sinflammatory state of
MetS by modifying the secretion of free fatty acids and adipocy-
tokines.24 Weight reduction and drug treatment of the metabolic
risk factors will reduce CRP levels and the underlying inflamma-
tory stimulus in MetS.40,115 Aspirin prophylaxis maybe considered
to counter the prothrombotic state of MetS predisposing to vas-
cular events.114
Treatment of NAFLD
NAFLD is the most common cause of chronic liver disease in the
Western world and the primary goal of treatment is to prevent
associated cardiac and liver-related morbidity and mortality.116
Weight loss
The current standard of care for NAFLD is weight loss which
improves liver histology, inflammatory markers and insulin resis-
tance a key aetiologic factor in NASH.115,117–122 A randomized con-
trolled trial to examine the effects of diet and exercise with a goal
of 7–10% weight reduction demonstrated a significant improve-
ment in serum aminotransferases and a reduction in NAS 3
points compared with the control group (72% vs. 30%).117 Long-
term efficacy of lifestyle interventions is generally disappointing
because of poor compliance; however, biochemical and histologic
improvements have been reported with short-term interventions
of 2–4 weeks.120–122 Significant histologic improvements reported
in prospective studies evaluating the effects of lifestyle interven-
tion in patients with NAFLD are shown in Table 4. In an effort to
improve utilization of steatotic livers in living–donor liver trans-
plantation,Nakamuta et al. treated 11moderately steatotic donors
with a short intensive treatment of a protein-rich diet (1000 kcal/
day), exercise (600 kcal/day) and bezafibrate (400 mg/day) for 2–8
weeks.27 There was a significant reduction in body weight, BMI,
normalization of liver function tests, lipid profile, biopsy-proven
macrovesicular steatosis (30 4% vs. 12 2%) in the donors and
the post-operative graft function was similar to donor livers
without steatosis. The treated donors showed good liver function
post-operatively and there was no difference in functional param-
eters between the treated and control groups. The best responders
in the study in terms of improvement of steatosis were patients
with a higher BMI. The authors concluded that the short-term
intensive treatment effectively reduced steatosis and contributed
to safer living-donor liver transplantation suggesting that even
severely steatotic livers can be used after their intensive regimen.
In a similar study of 23 potential living donors with fatty livers
using a diet and exercise regimen for weight loss over 1–3 months,
the authors reported a reduction in the hepatic fat content of
16.9% to 6.6% on biopsy.122 These data suggest that a pre-
operative weight reduction before hepatic resection in the pres-
ence of clinically significant steatosis is feasible and useful in
optimizing the peri-operative outcome.
Pharmacological treatment
A liver biopsy is required for histologic confirmation of NASH
before pharmacologic therapy. As the entire histological spec-
trum of NAFLD including NASH and bridging fibrosis can be
seen in individuals with normal alanine aminotransferase (ALT)
levels and low normal ALT does not guarantee freedom from
underlying steatohepatitis, serum transaminase levels cannot be
used for screening patients for NASH to enhance the yield of a
Table 4 Prospective studies on the effects of diet and exercise in NAFLD
Author Year N Indication Additional therapy Duration (months) Histologic Improvement
NAS Steatosis Fibrosis
Promrat117 RCT 2010 31 NASH 12 + + -
Hickman118 2004 14 NAFLD 6 + +
Nakamuta27 2005 11 Pre-transplant Bezafibrate ½–2 +
Chen122 2008 23 Pre-transplant 1–3 +
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NAS, NAFLD activity score; RCT, randomized controlled trial.
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liver biopsy.123 In contrast, the risk of developing NASH and
advanced fibrosis is related to increasing age, obesity and type 2
diabetes mellitus and the yield of a liver biopsy can be increased
by targeting patients with these risk factors.124 Pharmacologic
therapy should be considered in patients with active NASH to
reverse fibrosis and prevent cirrhosis; however, its role in
improving surgical outcome after hepatic resection is
unknown.125
Insulin sensitizers Insulin sensitizers improve insulin resistance
and promote fat redistribution from ectopic tissues, liver and
muscle to adipose tissue.126 Of the five randomized clinical trials
evaluating the efficacy of TZDs in NASH other than PIVENS
(Pioglitazone or Vitamin E for NASH Study) none were
adequately powered; however, they demonstrated some consistent
findings including an improvement in steatosis and liver enzymes
as shown in Table 5.125 Pioglitazone is preferred because of the
increased cardiovascular risk with rosiglitazone and it is reserved
for the second line treatment of NASH except in select patients
with diabetes and NASH where it is therapeutic for both
conditions.125,128,130
Antioxidants Oxidative stress and abnormal cytokine produc-
tion are ‘second hits’ in the development of NASH providing the
basis for antioxidant therapy with Vitamin E.131–136 Several ran-
domized controlled trials including PIVENS have demonstrated
the therapeutic efficacy of vitamin E in NASH as shown in Table 6.
Vitamin E therapy should not be considered without pathologic
confirmation of the nature of the liver disease and a-tocopherol
(800 IU/day) is recommended in patients with active NASH (NAS
4) without diabetes.125 Weight loss, TZDs and antioxidants are
the most extensively evaluated therapeutic strategies in the treat-
ment of NAFL; however, the clinical utility of these drugs in the
treatment of chemotherapy-associated steatohepatitis (CASH) is
unknown.137
Peri-operative strategies
MetS is a predictor of underlying steatosis or steatohepatitis sug-
gesting that patients who are potential candidates for a hepatic
resection should be screened for MetS. The selective use of a liver
biopsy in patients with multiple metabolic risk factors can identify
unsuspected NASH, a predictor of post-operative mortality.124
This will permit modification of the operative strategy by limiting
the extent of hepatic resection, avoiding or altering pre-operative
chemotherapy regimens and the use of PVE to optimize the post-
operative outcome. A standardized future liver remnant (sFLR) >
20% is adequate for the safe resection of a normal liver; however,
PVE should be considered in patients with sFLR  30% in the
presence of liver injury identified on the basis of clinical, labora-
tory, imaging or histologic data (30% steatosis or severe
fibrosis).138–140 PVE is also recommended in patients who have
received 6 cycles of chemotherapy as they are at an increased
risk for post-operative complications.141 Further clarification is
required on the issues of routine versus selective PVE in the pres-
ence of significant steatosis and the optimal sFLR based on the
severity of steatosis.142
Table 5 Randomized controlled trials evaluating the therapeutic efficacy of thiazolidinediones (insulin sensitizers) in NASH
Author Year N Intervention Comparator Duration
(months)
Histologic improvement
Steatosis Inflammation Fibrosis Hepatocyte injury
Sanyal26 2010 247 Pioglitazone or VitaminE Placebo 24 + + -
+ + -
Aithal127 2008 74 Pioglitazone Placebo 12 - - + +
Ratziu128 2008 63 Rosiglitazone Placebo 12 + - -
Belfort25 2006 55 Pioglitazone Placebo 6 + + - +
Sanyal129 2004 20 Pioglitazone + Vitamin E Vitamin E 6 + + +
NASH, non-alcoholic steatohepatitis.
Table 6 Randomized controlled trials evaluating the therapeutic efficacy of Vitamin E in NASH
Author Year N Intervention Comparator Duration (months) Histologic improvement
Steatosis Inflammation Fibrosis
Sanyal26 2010 247 Vitamin E or Pioglitazone Placebo 24 + + -
+ + -
Dufour136 2006 48 Vitamin E + UDCA UDCA + Placebo
or Placebo only
24 + - -
Sanyal129 2004 20 Vitamin E + Pioglitazone Vitamin E 6 + +
Harrison134 2003 49 Vitamin E + Vitamin C Placebo 6 - +
UDCA, ursodeoxycholic acid; NASH, non-alcoholic steatohepatitis.
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Irinotecan should be used with caution in patients with a BMI
25 kg/m2 and in patients withmultiple metabolic risk factors.As
a result of the risk of pre-existing steatosis or steatohepatitis,
consideration should be given to the avoidance of pre-operative
chemotherapy in favour of initial surgery for resectable colorectal
liver metastases and chemotherapy should be limited with short-
interval evaluations to proceed with surgery when resectability is
confirmed in borderline or unresectable tumours.110 A pre-
operative liver biopsy should be considered in patients at risk for
CASH and major hepatic resection should be avoided in those
with confirmed CASH. As imaging cannot accurately identify ste-
atohepatitis or sinusoidal injury and liver injury is not uniform,
laparoscopy with direct inspection and core biopsy before a lap-
arotomy is preferred over image-guided percutaneous biopsy.106
Sinusoidal injury results in blue liver syndrome, steatosis in a
yellow liver and non-specific findings of steatohepatitis include
hepatomegaly, fatty accumulation in the round ligament and
white or yellowmarkings or depressions on the surface of the liver.
Earlier studies have demonstrated that ischaemic precondition-
ing before continuous hepatic pedicle clamping reduces reperfu-
sion injury particularly in steatotic livers.143,144 Subsequent
randomized clinical trials have not confirmed a protective effect of
ischaemic preconditioning with no significant difference in the
mortality, liver failure, morbidity, blood loss, haemodynamic sta-
bility or hospital stay.145–147 Patients with MetS are at an increased
peri-operative risk of acute kidney injury which may be aggra-
vated by the low central venous pressure used for hepatic resection
to minimize blood loss. Higher peri-operative glucose levels and
glucose variability have been shown to be associated with
increased complications after various types of surgical procedures
including general, vascular, hepatobiliary and pancreatic
surgery.148–150 These patients may benefit from a tight glucose
control; however, MetS is characterized by insulin resistance and
glucose homeostasis will have to be balanced against the risk of
hypoglycaemia.151–153 MetS is associated with a prothrombotic
state and an increased risk for VTE; however, currently there are
no recommendations to modify standard prophylaxis for deep
vein thrombosis.154
In conclusion, patients who are potential candidates for liver
resection should be screened for the presence of MetS as they are
at a high risk for an adverse peri-operative outcome. CVD should
be managed aggressively in patients with MetS and NAFLD. Pre-
operative identification of NASH with the selective use of a liver
biopsy should prompt consideration of pharmacological therapy.
The extent of the hepatic resection, the use of chemotherapy and
PVE are influenced by the extent of parenchymal injury. Short-
term regimens for pre-operative weight loss may be considered in
patients with significant steatosis. Peri-operative measures to
minimize acute renal injury, thrombotic events and glucose
homeostasis may further improve the outcome. Prospective data
evaluating the peri-operative outcome after hepatic resection in
patients systematically screened for MetS will provide further
insight into the peri-operative management of these patients.
Additional research is required to identify the mechanisms
responsible for the increased operative mortality associated with
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